ADELY-01 is under clinical development by ADEL and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ADELY-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ADELY-01 is under development for the treatment of Alzheimer's disease and tauopathies. The therapeutic candidate is a monoclonal antibody which acts by targeting tau protein.
For a complete picture of ADELY-01’s drug-specific PTSR and LoA scores, buy the report here.